Team uses chemical compound to restore affected brain regions; findings could lead to new treatment strategies
Researchers have successfully disrupted a genetic chain of events in a mouse model of schizophrenia and reversed memory deficits, one of the disorder’s most difficult-to-treat symptoms. This discovery—which builds upon decades of early-stage research—could lead to more effective therapies for the cognitive symptoms of schizophrenia, a psychiatric disorder that affects more than 21 million people worldwide.
In a paper published today in the journal Neuron, scientists at Columbia’s Mortimer B. Zuckerman Mind Brain Behavior Institute,Columbia University Medical Center (CUMC) as well as the New York State Psychiatric Institute (NYSPI) used a chemical compound to regrow connections between brain cells, or neurons, which in turn restored memory deficits. The abnormal or stunted growth of neurons in the brain’s memory centers is a key indicator of schizophrenia.
The study was performed in mice with a specific genetic mutation known as the 22q11.2 microdeletion. This mutation, which occurs in one percent of people with schizophrenia, is the single largest genetic risk factor for the disease.
“With these findings, we showed that restoring cellular connections reversed memory deficits—a symptom of schizophrenia for which there is no effective treatment,” said Joseph Gogos, MD, PhD, a principal investigator at the Zuckerman Institute, professor of physiology and neuroscience at CUMC and a senior author of the paper. “This represents an invaluable new strategy for treating schizophrenia and highlights the critical importance of basic biological research in psychiatric disorders. Understanding how schizophrenia originates in our model lends critical insight into the disorder as a whole, paving the way for improved treatment options that have thus far remained elusive.”
Paranoia, auditory hallucinations and delusions are some of schizophrenia’s most well known symptoms and can often be controlled with antipsychotic medication. However, other symptoms—like severe disruptions to short-term and verbal memory, reduced attention and a decrease in IQ—have remained largely untreatable. Memory deficits can interfere with an individual’s ability to maintain relationships or a job—essentially cutting them off from the world around them.
“Memory deficits are now considered a core feature of schizophrenia and are believed to be strongly tied to the disorder’s underlying biology,” said Joshua Gordon, MD, PhD, associate professor of psychiatry at CUMC, a research scientist at NYSPI and a senior author of the paper. “Until we can shed light on that biology, these symptoms remain virtually impossible to treat.”
To address this, Dr. Gogos has spent nearly 20 years working to uncover the biological basis of schizophrenia. He and his collaborators developed a laboratory mouse model that exhibited the 22q11.2 microdeletion.
“Schizophrenia affects about one in every 100 people, but for those with a 22q11.2 microdeletion, that chance jumps to one in three,” said Dr. Gogos. “22q11.2 microdeletions remain the single greatest genetic risk factor for developing schizophrenia. This is why our model has proved invaluable in allowing us to trace schizophrenia back to its beginnings.”
In a study published last year, Drs. Gogos, Gordon and their research team revealed how the 22q11.2 microdeletion leads to weaker connections between neurons in key brain regions, resulting in schizophrenia’s memory deficits.
“Normally, neurons grow long branches that connect across long distances, forming tightly interconnected circuits,” said Dr. Gordon. “However, in our mouse models, these branches were stunted in the hippocampus and prefrontal cortex—two regions crucial for memory. Further experiments revealed why: a protein called Gsk3? was clogging the brain.”
Last year’s study showed that the 22q11.2 microdeletion kickstarts a chain reaction that boosts Gsk3? activity right from birth. Overactive Gsk3? stunts the growth and development of neurons in the brain’s memory centers. Over time, this hampers their ability to form strong connections.
In the new study, the researchers tested whether suppressing Gsk3? activity could reverse the damage that ultimately leads to schizophrenia’s memory deficits.
In a series of experiments, the researchers treated their mouse models at a young age (between seven and 28 days after birth), with a chemical compound that blocked Gsk3? activity. Almost immediately, they began to see a difference. As Gsk3? activity dropped, the neurons branched out and formed connections with their neighbors. Communication between brain regions was restored, and—importantly—the mice showed no memory deficits.
“Our work suggests that Gsk3? could be considered a potential target for treating some symptoms of schizophrenia—though there are limitations,” said Dr. Gordon. “For example, whether the same treatment might work in other models of schizophrenia that do not have the 22q11.2 microdeletion. Also, we treated the mice at a young age, but schizophrenia normally presents in adolescence and young adulthood.”
“We’re currently planning to test whether blocking Gsk3? during that equivalent age in our models would also have the same positive effect,” added Dr. Gogos.
“Schizophrenia is a complex disorder—there is no single cause—but disrupted communication between the hippocampus and prefrontal cortex may be a common thread running through many of them,” said Vikaas Sohal, MD, PhD, assistant professor of psychiatry at the University of California, San Francisco School of Medicine, who was not involved with the study.
“The findings presented here by Drs. Gogos, Gordon and their team could lead to additional ways of restoring normal communication between these two brain regions—and thus provide effective treatments for schizophrenia that arise from a variety of causes.”
Learn more: Scientists Eliminate Core Symptom of Schizophrenia in Mice
The Latest on: Schizophrenia
[google_news title=”” keyword=”schizophrenia” num_posts=”10″ blurb_length=”0″ show_thumb=”left”]
via Google News
The Latest on: Schizophrenia
- New study into identical twins suggests a possible treatment for people with schizophrenia disorderon May 7, 2024 at 4:11 pm
Research led by Prof. Shani Stern at the University of Haifa unveils genetic discrepancies in schizophrenia discordant monozygotic twins, offering insights for treatment.
- Haifa University, Salk Institute Report Findings on Genetic Causes of Schizophreniaon May 7, 2024 at 12:50 pm
The researchers chose to examine genetic differences between individuals who would not be expected to show such differences – pairs of identical twins, who should share the same DNA sequence, where ...
- INCREDIBLE SHRINKING BRAIN Shows the Physical Realities Behind Depression, Bipolar Disorder and Schizophrenia.on May 7, 2024 at 8:00 am
Respected psychiatrist states physical brain conditions are connected to depression, bipolar disorder, and schizophrenia in Palmetto Publishing’s latest book. The Incredible Shrinking Brain cover ...
- Battling schizophrenia for 8 years, Nair Hospital staffer jumps to death from 15th floor of apartmenton May 6, 2024 at 11:30 pm
Mumbai: A tragic incident unfolded on Monday afternoon after a 33-year-old employee of Nair Hospital in Mumbai Central died by allegedly jumping from the 15th floor of his apartments located ...
- A Sometimes Overlooked Schizophrenia and Psychosis Symptomon May 5, 2024 at 6:36 am
Emotional blunting is a common but often under-discussed symptom of schizophrenia. This isn't an absence of emotion, but an alteration and disconnect. There is help.
- Cat owners could be at higher risk of schizophrenia, study suggests, but more research neededon May 2, 2024 at 1:07 pm
Cat cuddles might seem therapeutic, but a study suggests this could have adverse mental health effects down the road. The study researcher and a psychologist weighed in on the findings.
- Max and Iggor Cavalera Announce Re-Recording of Sepultura’s Schizophrenia, Unveil “Escape to the Void”: Streamon May 1, 2024 at 11:15 am
The latest re-recorded early Sepultura album by the Cavalera brothers. Max and Iggor Cavalera Announce Re-Recording of Sepultura’s Schizophrenia, Unveil “Escape to the Void”: Stream ...
- Newron’s add-on schizophrenia therapy finds success in Phase II/III trialon May 1, 2024 at 3:22 am
The therapy met endpoints in the Phase II/III trial, with Newron considering a pivotal Phase III study in patients with treatment-resistant schizophrenia.
- Newron's schizophrenia add-on improves symptoms, charging up case for phase 3 teston April 30, 2024 at 2:13 am
Newron Pharmaceuticals’ add-on schizophrenia treatment improved both positive and negative symptoms as well as severity in patients with the disorder during a phase 2/3 study. The Italian biotech is ...
- Who Relapses From Schizophrenia?on April 29, 2024 at 7:17 am
A study identified a large population of patients with schizophrenia and examined factors related to relapse. Factors of relapse had to do with race, insurance access, and medication nonadherence, ...
via Bing News